Furkan Sarici

Ankara, Turkey

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.

Efficacy and safety evaluation of eribulin-trastuzumab combination therapy with heavily pretreated HER2-positive metastatic breast cancer.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: January 17, 2021

Association between androgen receptor status and prognosis in triple negative breast cancer.

Association between androgen receptor status and prognosis in triple negative breast cancer.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: December 21, 2018

Prognostic role of inflammatory biomarkers in metastatic breast cancer.

Prognostic role of inflammatory biomarkers in metastatic breast cancer.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: July 22, 2017

Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.

Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: September 30, 2016

Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: June 09, 2016

Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors.

Assessment of psychosocial factors and distress in women having adjuvant endocrine therapy for breast cancer: the relationship among emotional distress and patient and treatment-related factors.

Journal: SpringerPlus

Published: April 09, 2016

The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.

The lymph node ratio as an independent prognostic factor for non-metastatic node-positive breast cancer recurrence and mortality.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: July 28, 2015

Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.

Chemotherapy might not be beneficial in lymph node- negative, hormone-positive, and HER2-negative breast cancer patients: a long-term retrospective analysis.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: May 27, 2015

A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.

A retrospective analysis of adjuvant CAF, AC-T and TAC regimens in triple negative early stage breast cancer.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: March 18, 2015

The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients.

The effect of renin-angiotensin-system inhibition on survival and recurrence of N3+ breast cancer patients.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: March 18, 2015

Molecular subtypes in patients with inflammatory breast cancer; a single center experience.

Molecular subtypes in patients with inflammatory breast cancer; a single center experience.

Journal: Journal of B.U.ON. : official journal of the Balkan Union of Oncology

Published: March 18, 2015

Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.

Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer.

Journal: Tumori

Published: February 24, 2015

Showing 1-12 of 28

Last Updated: 09/26/2026